CIK 1940272
ADAR1 Capital Management, LLC
Institutional 13F holdings & portfolio
Holdings
512
Portfolio Value
$1M+
Latest Report
Dec 31, 2025
Report Periods
1
Holdings
13F filings as of Dec 31, 2025 · Showing 351–400 of 512
| Ticker | Company | Shares | Value | Type |
|---|---|---|---|---|
| CNTX | CONTEXT THERAPEUTICS INC | 351K | $500K+ | SH |
| CNTX | CONTEXT THERAPEUTICS INC | 351K | $500K+ | SH |
| GTERU | GLOBA TERRA ACQUISITION COR | 50K | $500K+ | SH |
| GTERU | GLOBA TERRA ACQUISITION COR | 50K | $500K+ | SH |
| USFR | WISDOMTREE TR | 10K | $500K+ | SH |
| USFR | WISDOMTREE TR | 10K | $500K+ | SH |
| APLS | APELLIS PHARMACEUTICALS INC | 20K | $500K+ | SH |
| APLS | APELLIS PHARMACEUTICALS INC | 20K | $500K+ | SH |
| NTRA | NATERA INC | 2K | $100K–$500K | SH |
| NTRA | NATERA INC | 2K | $100K–$500K | SH |
| BSX | BOSTON SCIENTIFIC CORP | 5K | $100K–$500K | SH |
| BSX | BOSTON SCIENTIFIC CORP | 5K | $100K–$500K | SH |
| ELVN | ENLIVEN THERAPEUTICS INC | 30K | $100K–$500K | SH |
| ELVN | ENLIVEN THERAPEUTICS INC | 30K | $100K–$500K | SH |
| ELAN | ELANCO ANIMAL HEALTH INC | 20K | $100K–$500K | SH |
| ELAN | ELANCO ANIMAL HEALTH INC | 20K | $100K–$500K | SH |
| PYPD | POLYPID LTD | 104K | $100K–$500K | SH |
| PYPD | POLYPID LTD | 104K | $100K–$500K | SH |
| GERN | GERON CORP | 336K | $100K–$500K | SH |
| GERN | GERON CORP | 336K | $100K–$500K | SH |
| PRAX | PRAXIS PRECISION MEDICINES I | 2K | $100K–$500K | SH |
| PRAX | PRAXIS PRECISION MEDICINES I | 2K | $100K–$500K | SH |
| NVCR | NOVOCURE LTD | 34K | $100K–$500K | SH |
| NVCR | NOVOCURE LTD | 34K | $100K–$500K | SH |
| CORZ | CORE SCIENTIFIC INC NEW | 30K | $100K–$500K | SH |
| CORZ | CORE SCIENTIFIC INC NEW | 30K | $100K–$500K | SH |
| KURA | KURA ONCOLOGY INC | 40K | $100K–$500K | SH |
| KURA | KURA ONCOLOGY INC | 40K | $100K–$500K | SH |
| VTGN | VISTAGEN THERAPEUTICS INC | 624K | $100K–$500K | SH |
| VTGN | VISTAGEN THERAPEUTICS INC | 624K | $100K–$500K | SH |
| BHVN | BIOHAVEN LTD | 34K | $100K–$500K | SH |
| BHVN | BIOHAVEN LTD | 34K | $100K–$500K | SH |
| KROS | KEROS THERAPEUTICS INC | 19K | $100K–$500K | SH |
| KROS | KEROS THERAPEUTICS INC | 19K | $100K–$500K | SH |
| KPTI | KARYOPHARM THERAPEUTICS INC | 50K | $100K–$500K | SH |
| KPTI | KARYOPHARM THERAPEUTICS INC | 50K | $100K–$500K | SH |
| KIDS | ORTHOPEDIATRICS CORP | 20K | $100K–$500K | SH |
| KIDS | ORTHOPEDIATRICS CORP | 20K | $100K–$500K | SH |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 45K | $100K–$500K | SH |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 45K | $100K–$500K | SH |
| AUPH | AURINIA PHARMACEUTICALS INC | 22K | $100K–$500K | SH |
| AUPH | AURINIA PHARMACEUTICALS INC | 22K | $100K–$500K | SH |
| DAY | DAYFORCE INC | 5K | $100K–$500K | SH |
| DAY | DAYFORCE INC | 5K | $100K–$500K | SH |
| TXMD | THERAPEUTICSMD INC | 209K | $100K–$500K | SH |
| TXMD | THERAPEUTICSMD INC | 209K | $100K–$500K | SH |
| KPRX | KIORA PHARMACEUTICALS INC | 168K | $100K–$500K | SH |
| KPRX | KIORA PHARMACEUTICALS INC | 168K | $100K–$500K | SH |
| JBIO | JADE BIOSCIENCES INC | 21K | $100K–$500K | SH |
| JBIO | JADE BIOSCIENCES INC | 21K | $100K–$500K | SH |